Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
| Revenue (TTM) | $819.56M |
| Gross Profit (TTM) | $670.48M |
| EBITDA | $-949.04M |
| Operating Margin | -65.50% |
| Return on Equity | -294.50% |
| Return on Assets | -31.10% |
| Revenue/Share (TTM) | $3.95 |
| Book Value | $3.25 |
| Price-to-Book | 33.68 |
| Price-to-Sales (TTM) | 28.10 |
| EV/Revenue | 28.18 |
| EV/EBITDA | -6.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 229.60% |
| Shares Outstanding | $216.75M |
| Float | $198.27M |
| % Insiders | 0.53% |
| % Institutions | 105.23% |
Volatility is currently contracting